09:20 AM EDT, 06/17/2024 (MT Newswires) -- Health care stocks were declining premarket Monday with the Health Care Select Sector SPDR Fund ( XLV ) recently 0.3% lower and the iShares Biotechnology ETF ( IBB ) down 0.5%.

Nurix Therapeutics ( NRIX ) was up more than 11% after saying an ongoing phase 1a/b clinical trial of its drug NX-5948 is yielding what one of its researchers called "impressive" results for the treatment of adult patients with relapsed or refractory B-cell malignant cancers such as non-Hodgkin lymphoma.

Ovid Therapeutics ( OVID ) sank by over 66% after it distanced itself from Takeda (TAK) after its potential epilepsy and neurology drug soticlestat failed to meet its primary endpoints in phase 3 studies. Ovid, which sold its rights to soticlestat back to Takeda three years ago, said it was "surprised and disappointed" by the results of the studies.

Marinus Pharmaceuticals ( MRNS ) was down more than 7% after saying its experimental drug, intravenous ganaxolone, aimed at treating refractory status epilepticus - a condition where seizures persist despite standard treatments - did not achieve one of its primary goals in a phase 3 study, sending shares down by 8% in premarket trading.